Target intelligence / Profile preview

UDP-glucose glycoprotein glucosyltransferase 2 (UGGT2)

Target
UGGT2
Molecular classification
Enzyme, Glycosyltransferase (GT24 fold family), ER quality control factor
01

Overview

UDP-glucose glycoprotein glucosyltransferase 2 (UGGT2) is an ER-resident glucosyltransferase and quality control sensor protein. It selectively reglucosylates misfolded N-glycoproteins, enabling their reassociation with lectin chaperones which retain them in the ER and facilitate further folding attempts or target them for degradation if proper folding is not restored. Unlike its paralogue UGGT1, which modifies a broader range of glycoproteins including large plasma membrane proteins, UGGT2 is preferentially active against smaller soluble lysosomal proteins. The function of UGGT2 is essential in maintaining secretory pathway integrity, and its misregulation has been linked to protein folding diseases. No approved drugs currently target UGGT2 directly, but its activity is critical for the proper folding and quality control of many secreted and lysosomal proteins, and thus indirectly relevant to the efficacy and safety of therapeutic biologics.

Other names
UGCGL2UGT2hUGT2FLJ11485HUGT2FLJ10873MGC150689MGC87276MGC117360UDP--Glc:glycoprotein glucosyltransferase 2UDP-glucose ceramide glucosyltransferase-like 1UDP-glucose ceramide glucosyltransferase-like 2
02

Mechanism of action

Putative inhibitors or modulators would affect ER quality control and glycoprotein maturation (no known drugs)

03

Biological functions

Glycoprotein folding quality control in ERReglucosylation of misfolded N-glycoproteinsFacilitating interaction with lectin chaperones (calnexin, calreticulin)Preventing premature export of misfolded glycoproteinsPromoting ER-associated degradation (ERAD)
04

Disease associations

Protein folding diseases (Congenital disorders of glycosylation, lysosomal storage diseases)Potential roles in neurodegeneration, certain cancers, and metabolic diseases due to involvement in proteostasis
05

Safety considerations

Modulation might lead to widespread protein misfolding, ER stress, or altered secretion/degradation, impacting multiple organ systemsTherapeutic challenges: targeting could cause off-target effects due to ubiquity of glycoprotein folding pathways

Beyond the preview

Go deeper on UDP-glucose glycoprotein glucosyltransferase 2 (UGGT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UDP-glucose glycoprotein glucosyltransferase 2 (UGGT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call